Nasal Steroid Spray for MS Relapses
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a nasal spray form of the steroid methylprednisolone for treating MS relapses. The goal is to see if this new way of taking the medicine works as well or better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have relapsing-remitting MS (RRMS) and have been diagnosed for at least 3 months but no more than 10 years.
- Your disability level should be mild to moderate (able to walk with or without a cane).
- You cannot have taken steroids (like prednisone) in the last 3 days.
- You must not have certain health issues like high blood pressure, diabetes, active infections, glaucoma, or a history of nasal problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a nasal spray made from mastic oil combined with a lower dose of a standard steroid medication (mometasone) for people with chronic sinusitis. It aims to see if this combination is effective in reducing symptoms.
This Phase 2 study tests whether corticosteroid medicine can reduce inflammation at the edge of active multiple sclerosis (MS) plaques seen on MRI. It may help calm “hot” areas in the brain where MS activity is happening.
This trial tests a nasal spray called Bactorinol combined with a lower dose of a standard steroid (mometasone) to treat chronic sinusitis. It aims to see if the combination reduces symptoms and is safe and well-tolerated.
This study tests a nebulized nasal steroid treatment for chronic rhinosinusitis (CRS), which causes long-lasting nasal congestion, runny nose, loss of smell, or facial pain. The treatment goals to reduce symptoms and improve daily comfort.
This study provides access to an experimental nasal spray medication called foralumab for people with a specific type of MS that has stopped responding to standard treatments. The goal is to see if the drug can slow or stop disability progression.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.